The Shotlee Journal
Browse Shotlee articles about Metabolic Health.
Showing 9 / 741 Metabolic Health articles
Eli Lilly's experimental drug Retatrutide is making waves with unprecedented weight loss results in clinical trials, potentially setting a new benchmark in obesity treatment. This comprehensive look examines its efficacy, mechanism, and comparison to existing GLP-1 and GIP agonists.
Obesity is a complex, multi-organ disease, not a failure of willpower. This article delves into its metabolic underpinnings and outlines a practical approach to management, including modern medications and lifestyle adjustments.
The advent of GLP-1 receptor agonists has transformed the landscape of weight management, offering new hope for individuals struggling with obesity. This article delves into the science, benefits, potential drawbacks, and the leading players in this groundbreaking field.
A new controlled study suggests that swapping processed snacks for a daily serving of almonds can enhance gut bacteria, lower inflammation, and increase satiety hormones like GLP-1.
Peptides offer targeted health benefits, from weight loss to injury healing, but safety varies significantly. Explore the science, risks, and medical guidance required.
Peptides are powerful signaling molecules, but they are not a universal cure-all. This deep dive clarifies the function of GLP-1 agonists, cosmetic peptides, and the critical importance of medical guidance when considering peptide therapies for weight management or anti-aging.
The race for dominance in the lucrative weight loss drug market is intensifying. While Novo Nordisk's Wegovy has been a pioneer, Eli Lilly is rapidly advancing its pipeline with next-generation therapies poised to challenge the status quo. This article delves into the science, clinical data, and market implications of these groundbreaking treatments.
Discover the key factors propelling eBay's stock to new heights, from strategic acquisitions and a focus on recommerce to strong financial performance and positive analyst sentiment. This article unpacks the company's success and its implications.
GLP-1 receptor agonists, widely known for their efficacy in weight management and type 2 diabetes, are showing remarkable promise in addressing Alcohol Use Disorder (AUD). Emerging research suggests these injectable therapies may fundamentally alter the brain's reward pathways, offering a novel pharmaceutical path for those struggling with heavy drinking.
